Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy

J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):e112-e114. doi: 10.1097/QAI.0000000000001863.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Female
  • Genitalia / virology*
  • Genotyping Techniques
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / isolation & purification*
  • Heterocyclic Compounds, 3-Ring / therapeutic use*
  • Humans
  • Lamivudine / therapeutic use*
  • Male
  • Oxazines
  • Piperazines
  • Pyridones
  • RNA, Viral / isolation & purification
  • Treatment Outcome
  • Virus Shedding*

Substances

  • Anti-HIV Agents
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • RNA, Viral
  • Lamivudine
  • dolutegravir